Modified APTT Screening for Excluding Factor XIa Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for a rapid and simple diagnostic method to determine the presence of factor XIa inhibitors in patient samples, which are not addressed by existing chromogenic or coagulometric tests, especially for patients in urgent medical situations where anticoagulant therapy is unknown.
Innovation Solution
A modified APTT test using factor XI-deficient plasma and a neutralizing substance to neutralize non-factor XIa inhibitors, followed by determining the APTT quotient, allowing exclusion of factor XIa inhibitors based on a predetermined reference value.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional chromogenic or coagulometric tests are used to detect coagulation factors, then general coagulation factor activity can be measured, but specific detection of factor XIa inhibitors is not achieved
Solution Approach 1:
The patent extracts and isolates the specific detection of factor XIa inhibitors from general coagulation factor detection by using factor XI-deficient plasma as the test substrate. This extraction allows the test to specifically identify factor XIa inhibitors while excluding other anticoagulants, directly resolving the contradiction between measurement precision for specific inhibitors and adaptability to unknown therapy cases.
Solution Approach 2:
The patent applies local quality by creating a specialized test environment using factor XI-deficient plasma that has unique properties tailored for detecting factor XIa inhibitors. This localized modification of the test substrate gives the method high specificity for factor XIa inhibitors while maintaining broad applicability to patients with unknown anticoagulant therapy.
2Productivity
If a rapid diagnostic method is implemented for urgent medical situations, then treatment time is reduced, but diagnostic accuracy for specific inhibitor types may be compromised
Solution Approach 1:
The patent segments the diagnostic process into a simple, rapid APTT-based test using factor XI-deficient plasma that can quickly identify factor XIa inhibitors. This segmented approach separates the specific detection of factor XIa inhibitors from more complex confirmatory tests, enabling rapid initial assessment in urgent situations while maintaining high diagnostic accuracy through the specific substrate used.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The method provides high sensitivity and specificity for excluding factor XIa inhibitors, enabling rapid assessment of coagulation status in patients, particularly in emergency surgical scenarios.
Implementation Method 1
at least one neutralizing substance which neutralizes an anticoagulant other than an anticoagulant from the group of factor XIa inhibitors
Implementation Method 2
Factor XI is a component of the intrinsic blood coagulation system and is activated by activated factor XII or by thrombin and it itself activates factor IX
Implementation Method 3
A cascade of enzymatic processes, with each enzyme activating a further enzyme through proteolytic processes, ends in fibrin formation, which contributes to the formation of wound-closing blood clots
Data Source
AI summary
The present disclosure is in the field of coagulation diagnostics and relates to a method for excluding anticoagulants from the group of factor XIa inhibitors in a patient sample.